CR20230496A - Compuestos heterocíclicos - Google Patents
Compuestos heterocíclicosInfo
- Publication number
- CR20230496A CR20230496A CR20230496A CR20230496A CR20230496A CR 20230496 A CR20230496 A CR 20230496A CR 20230496 A CR20230496 A CR 20230496A CR 20230496 A CR20230496 A CR 20230496A CR 20230496 A CR20230496 A CR 20230496A
- Authority
- CR
- Costa Rica
- Prior art keywords
- sup
- heterocyclic compounds
- compounds
- thecompounds
- processes
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención proporciona nuevos compuestos heterocíclicos que tienen la fórmula general (I) en donde A, B, C, L y R<sup>1</sup> a R<sup>7</sup> son como se describe en la presente, composiciones que incluyen los compuestos, procesos para elaborar los compuestos y métodos para usar los compuestos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21170090 | 2021-04-23 | ||
| CN2022083125 | 2022-03-25 | ||
| PCT/EP2022/060644 WO2022223750A1 (en) | 2021-04-23 | 2022-04-22 | Heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20230496A true CR20230496A (es) | 2023-11-15 |
Family
ID=81750728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20230496A CR20230496A (es) | 2021-04-23 | 2022-04-22 | Compuestos heterocíclicos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240199587A1 (es) |
| EP (1) | EP4326714A1 (es) |
| JP (1) | JP2024521618A (es) |
| KR (1) | KR20240000574A (es) |
| CN (1) | CN117295726A (es) |
| AR (1) | AR125401A1 (es) |
| AU (1) | AU2022260537A1 (es) |
| CA (1) | CA3215260A1 (es) |
| CL (1) | CL2023003154A1 (es) |
| CO (1) | CO2023014721A2 (es) |
| CR (1) | CR20230496A (es) |
| IL (1) | IL306126A (es) |
| MX (1) | MX2023012477A (es) |
| PE (1) | PE20240239A1 (es) |
| TW (1) | TW202309010A (es) |
| WO (1) | WO2022223750A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3837263T3 (fi) | 2018-08-13 | 2024-09-03 | Hoffmann La Roche | Uusia heterosyklisiä yhdisteitä monoasyyliglyserolilipaasin estäjinä |
| JP7444882B2 (ja) | 2018-11-22 | 2024-03-06 | エフ. ホフマン-ラ ロシュ アーゲー | 新規の複素環化合物 |
| AU2022426844A1 (en) * | 2021-12-29 | 2024-07-04 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| WO2023130050A1 (en) * | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Monoacylglycerol lipase inhibitors and use thereof for the treatment and management of pain |
| US20250170100A1 (en) * | 2021-12-29 | 2025-05-29 | Psy Therapeutics, Inc. | Monoacylglycerol lipase inhibitors and use thereof for the treatment of anxiety and related conditions |
| AU2023211077A1 (en) * | 2022-01-25 | 2024-07-04 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
| WO2023247670A1 (en) * | 2022-06-24 | 2023-12-28 | F. Hoffmann-La Roche Ag | New heterocyclic-carbonyl-cyclic compounds as magl inhibitors |
| CA3261681A1 (en) | 2022-08-05 | 2024-02-08 | Kumquat Biosciences Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| WO2024215863A2 (en) * | 2023-04-13 | 2024-10-17 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| WO2025010394A2 (en) * | 2023-07-06 | 2025-01-09 | Psy Therapeutics, Inc. | Monoacylglycerol lipase inhibitors and use thereof for the treatment and management of inflammatory conditions |
| WO2025010392A2 (en) * | 2023-07-06 | 2025-01-09 | Psy Therapeutics, Inc. | Monoacylglycerol lipase inhibitors and use thereof for the treatment of neurological disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA035185B1 (ru) * | 2014-10-08 | 2020-05-12 | Ф. Хоффманн-Ля Рош Аг | Производные спиродиамина в качестве ингибиторов альдостеронсинтазы |
| MA42293A (fr) * | 2015-07-02 | 2018-05-09 | Janssen Sciences Ireland Uc | Composés antibactériens |
| US10538530B2 (en) * | 2017-09-05 | 2020-01-21 | Blackthorn Therapeutics, Inc. | Vasopressin receptor antagonists and products and methods related thereto |
| US11542282B2 (en) * | 2018-02-28 | 2023-01-03 | The Trustees Of The University Of Pennsylvania | Low affinity poly(AD-ribose) polymerase 1 dependent cytotoxic agents |
| JP2021522253A (ja) * | 2018-04-25 | 2021-08-30 | ユマニティ セラピューティクス,インコーポレーテッド | 化合物及びその使用 |
| JP7444882B2 (ja) * | 2018-11-22 | 2024-03-06 | エフ. ホフマン-ラ ロシュ アーゲー | 新規の複素環化合物 |
| CN111793064B (zh) * | 2019-04-02 | 2023-06-23 | 上海美悦生物科技发展有限公司 | 一种作为irak抑制剂的化合物及其制备方法和用途 |
| KR20230074520A (ko) * | 2020-09-22 | 2023-05-30 | 얀센 파마슈티카 엔.브이. | 사이클로부틸 아미드 모노아실글리세롤 리파제 조절제 |
-
2022
- 2022-04-22 MX MX2023012477A patent/MX2023012477A/es unknown
- 2022-04-22 PE PE2023002921A patent/PE20240239A1/es unknown
- 2022-04-22 AU AU2022260537A patent/AU2022260537A1/en active Pending
- 2022-04-22 CA CA3215260A patent/CA3215260A1/en active Pending
- 2022-04-22 KR KR1020237040339A patent/KR20240000574A/ko active Pending
- 2022-04-22 AR ARP220101039A patent/AR125401A1/es unknown
- 2022-04-22 CR CR20230496A patent/CR20230496A/es unknown
- 2022-04-22 IL IL306126A patent/IL306126A/en unknown
- 2022-04-22 TW TW111115346A patent/TW202309010A/zh unknown
- 2022-04-22 WO PCT/EP2022/060644 patent/WO2022223750A1/en not_active Ceased
- 2022-04-22 JP JP2023564563A patent/JP2024521618A/ja active Pending
- 2022-04-22 CN CN202280030020.6A patent/CN117295726A/zh active Pending
- 2022-04-22 EP EP22724696.4A patent/EP4326714A1/en active Pending
-
2023
- 2023-10-20 CL CL2023003154A patent/CL2023003154A1/es unknown
- 2023-10-20 US US18/490,967 patent/US20240199587A1/en active Pending
- 2023-10-30 CO CONC2023/0014721A patent/CO2023014721A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR125401A1 (es) | 2023-07-12 |
| KR20240000574A (ko) | 2024-01-02 |
| JP2024521618A (ja) | 2024-06-04 |
| CN117295726A (zh) | 2023-12-26 |
| PE20240239A1 (es) | 2024-02-16 |
| AU2022260537A1 (en) | 2023-09-21 |
| CA3215260A1 (en) | 2022-10-27 |
| WO2022223750A1 (en) | 2022-10-27 |
| CO2023014721A2 (es) | 2023-11-20 |
| IL306126A (en) | 2023-11-01 |
| US20240199587A1 (en) | 2024-06-20 |
| TW202309010A (zh) | 2023-03-01 |
| MX2023012477A (es) | 2023-11-03 |
| EP4326714A1 (en) | 2024-02-28 |
| CL2023003154A1 (es) | 2024-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023012477A (es) | Compuestos heterociclicos. | |
| MX2023002224A (es) | Compuestos heterociclicos. | |
| EP4474017A3 (en) | New heterocyclic compounds | |
| PH12021551167A1 (en) | New heterocyclic compounds | |
| MX2023012907A (es) | Inhibidores de inflamasoma proteina 3 que contiene dominios de pirina (nlrp3). | |
| CR20200416A (es) | Nuevos compuestos heterocíclicos | |
| PH12022550433A1 (en) | Heterocyclic compounds | |
| CR20240158A (es) | Compuestos heteroarilo bicíclicos fusionados útiles como inhibidores de nlrp3 | |
| PH12022550472A1 (en) | New heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| ZA202005326B (en) | Heteroaryl compounds as type ii irak inhibitors and uses hereof | |
| CR20220004A (es) | Nuevos compuestos heterocíclicos | |
| MX2023009045A (es) | Derivados novedosos de pirimidin-2-il sulfonamida. | |
| ZA202213152B (en) | Novel acid secretion inhibitor and use thereof | |
| CR20220478A (es) | Derivados de benzodiazepinas como pam de gaba a gamma 1 | |
| MX2025005972A (es) | Compuestos novedosos como moduladores de la inhibicion de la proteina 3 que contiene un dominio de pirina de la familia de receptores similares al dominio de oligomerizacion de union a nucleotidos (nlrp3) | |
| MX2020013827A (es) | Proceso de preparacion de compuestos triciclicos. | |
| MX2020002449A (es) | Nuevos compuestos heterociclicos fungicidas. | |
| ZA202402459B (en) | Compounds for regulating trained immunity, and their methods of use | |
| ZA202500287B (en) | Crystalline forms of 1,2,4-oxadiazole fungicides | |
| MX2022010957A (es) | Compuestos que se dirigen a las proteínas de unión al arn o a las proteínas modificadoras del arn. | |
| MX2025001765A (es) | Derivados deuterados de pirimidin-2-il sulfonamida | |
| MX2023005713A (es) | Nuevo proceso para la elaboracion de derivados de tetrazol. | |
| MX2022010675A (es) | Composiciones que comprenden profarmacos de metilfenidato, procesos de elaboracion y uso de los mismos. | |
| MX2025000919A (es) | Derivados biciclicos de tetrahidrotiazepina | |
| MX2025000918A (es) | Derivados de tetrahidrotiazepina biciclicos |